Relatlimab plus nivolumab (anti–LAG-3+anti–PD-1) combination therapy has shown a progression-free survival benefit over anti–PD-1 monotherapy as a first-line treatment for patients with metastatic melanoma (11) and has now been approved by the FDA. Here, PDCD1 is linked to metastatic melanoma.